Randomized Controlled Study of Metformin and Sitagliptin on Long-term Normoglycemia Remission in African American Patients With Hyperglycemic Crises
Open accessThe DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: After intensive insulin treatment, many obese African American patients with new-onset diabetic ketoacidosis (DKA) and severe hyperglycemia are able to achieve near-normoglycemia remission. The optimal treatment to prevent hyperglycemic relapses after remission is not known. RESEARCH DESIGN AND METHODS: This prospective, 4-year, placebo-controlled study randomly assigned 48 African American subjects with DKA and severe hyperglycemia to metformin 1,000 mg daily (n = 17), sitagliptin 100 mg daily (n = 16), or placebo (n = 15) after normoglycemia remission. Hyperglycemic relapse was defined as fasting glucose >130 mg/dL (7.2 mmol/L) and HbA1c >7.0% (53 mmol/mol). Oral glucose tolerance tests were conducted at randomization and at 3 months and then every 6 months for a median of 331 days. Oral minimal model and incremental area under the curve for insulin (AUCi) were used to calculate insulin sensitivity (Si) and β-cell function, respectively. Disposition index (DI) was calculated as a product of Si and incremental AUCi. RESULTS: Relapse-free survival was higher in sitagliptin and metformin (P = 0.015) compared with placebo, and mean time to relapse was significantly prolonged in the metformin and sitagliptin groups compared with the placebo group (480 vs. 305 days, P = 0.004). The probability of relapse was significantly lower for metformin (hazard ratio 0.28 [95% CI 0.10–0.81]) and sitagliptin (0.31 [0.10–0.98]) than for placebo. Subjects who remained in remission had a higher DI (P = 0.02) and incremental AUCi (P < 0.001) than those with hyperglycemia relapse without significant changes in Si. CONCLUSIONS: This study shows that near-normoglycemia remission was similarly prolonged by treatment with sitagliptin and metformin. The prolongation of remission was due to improvement in β-cell function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, DKA can also occur in persons with T2D.28–31”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Standards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Hyperglycemic crises in adult patients with diabetes
Kitabchi, A. E., Umpierrez, G. E., Miles, J. M., & Fisher, J. N. (2009) · Diabetes Care · doi:10.2337/dc09-9032 · Cited by 2,062 · cited 1×
“30andbicarbonate $18 mmol/L and without ketonemia (b-hydroxybutyrate#3 mmol/L) (21).”
Self-citationRoyston, P., & Parmar, M. K. (2013) · BMC Medical Research Methodology · doi:10.1186/1471-2288-13-152 · Cited by 1,062 · cited 1×
“Because of the low number of subjects with hyperglycemia relapse and censoring in the medication groups, we calculated restricted mean survival time to estimate time to hyperglycemia relapse between the combined medication and placebo groups (27,28).”
MethodWeng, J., Li, Y., Xu, W., Shi, L., Zhang, Q., Zhu, D., Hu, Y., Zhou, Z., Yan, X., Tian, H., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60762-x · Cited by 780 · cited 1×
“The current findings are also similar to those of reports in subjects with newly diagnosed type 2 diabetes in whom intensive therapy and tight glucose control resulted in significant improvement in b-cell function (30,31).”
ResultTai, M. M. (1994) · Diabetes Care · doi:10.2337/diacare.17.2.152 · Cited by 498 · cited 1×
“For calculation of incremental AUCi, 15-, 30-, 60-, 90-, and 120-min time point insulin levels were subtracted from fasting insulin levels, and incremental AUCi was calculated with use of the trapezoidal method (25).”
MethodStentz, F. B., Umpierrez, G. E., Cuervo, R., & Kitabchi, A. E. (2004) · Diabetes · doi:10.2337/diabetes.53.8.2079 · Cited by 497 · cited 1×
“Insulin and C-peptide levels were measured by two-site sequential chemiluminescent immunometric assays as previously described (26).”
MethodSelf-citationHerman, G. A., Bergman, A., Stevens, C., Kotey, P., Yi, B., Zhao, P., Dietrich, B., Golor, G., Schrodter, A., Keymeulen, B., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1009 · Cited by 495 · cited 1×
“It prolongs the half-life of incretin hormones GLP-1 and gastric inhibitory polypeptide, which in turn potentiate glucose-mediated insulin release from the b-cell (19).”
BackgroundLi, Y., Xu, W., Liao, Z., Yao, B., Chen, X., Huang, Z., Hu, G., & Weng, J. (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2597 · Cited by 323
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Self-citationDiabetic ketoacidosis: A common debut of diabetes among African Americans with type 2 diabetes
Vellanki, P., & Umpierrez, G. E. (2017) · Endocrine Practice · doi:10.4158/ep161679.ra · Cited by 73
Self-citationHyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State
Umpierrez, G. E. (2020) · Endocrinology · doi:10.1007/978-3-030-36694-0_21 · Cited by 43
Self-citationRameshrad, M., Razavi, B. M., Ferns, G. A. A., & Hosseinzadeh, H. (2019) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-019-00238-7 · Cited by 34
Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State
Umpierrez, G. E. (2018) · Endocrinology · doi:10.1007/978-3-319-27316-7_21-1 · Cited by 30
Self-citationEvaluation and management of ketosis-prone diabetes
Gaba, R., Mehta, P. B., & Balasubramanyam, A. (2018) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2019.1561270 · Cited by 23
Ketosis-Prone Type 2 Diabetes: A Case Series
Sjöholm, Å. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00684 · Cited by 23
“There is only one (very recent) small randomized clinical trial that shows that sitagliptin and metformin appear equal in terms of maintaining remission in KPT2 (45).”
BackgroundHyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State
Umpierrez, G. E. (2019) · Endocrinology · doi:10.1007/978-3-319-27316-7_21-2 · Cited by 17
Self-citationEthnic diversity in precision medicine: a reality or an aspiration?
Misra, S. (2025) · Diabetologia · doi:10.1007/s00125-025-06513-4 · Cited by 17
Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State
Umpierrez, G. E. (2018) · Endocrinology · doi:10.1007/978-3-319-44433-8_21 · Cited by 12
Self-citationPopulation insulin sensitivity from sparsely sampled oral glucose tolerance tests
Stefanovski, D., Vellanki, P., Smiley, D. D., Umpierrez, G. E., & Boston, R. C. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154298 · Cited by 11
“Subject Recruitment: We included 64 obese African American subjects from a previous study (19).”
BackgroundSelf-citationGlobal Burden of Diabetic Ketoacidosis
Mohan, V., & Lee, K. (2025) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251390828 · Cited by 13
“71 As additional research further elucidates the underlying mechanisms of KPD, clinicians may need to modify their approaches to diagnosing and treating this condition to manage it more effectively.”
Remission in Ketosis-Prone Diabetes
Kikani, N. J., & Balasubramanyam, A. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.06.005 · Cited by 11
Type 2 Diabetes Mellitus non-surgical remission: A possible mission
Allam, M. M., & El‐Zawawy, H. T. (2019) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2019.100206 · Cited by 9
Vellanki, P., Stefanovski, D., Anzola, I., Smiley, D. D., Peng, L., & Umpierrez, G. E. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-001062 · Cited by 9
Self-citationKetosis-Prone Type 2 Diabetes Mellitus: An Unusual Presentation
Makahleh, L., Othman, A., Vedantam, V., & Vedantam, N. (2022) · Cureus · doi:10.7759/cureus.30031 · Cited by 9
“A small clinical trial has shown that metformin and sitagliptin are similarly effective in prolonging normoglycemic remission in KPT2D patients [14].”
BackgroundWu, S., Zhang, C.-C., Chen, J., Zhang, X., Guan, M., & Geng, C. (2022) · Fitoterapia · doi:10.1016/j.fitote.2022.105336 · Cited by 7
Raubenheimer, P. J., Skelton, J., Peya, B., Dave, J. A., & Levitt, N. S. (2024) · Diabetologia · doi:10.1007/s00125-023-06067-3 · Cited by 6
“Vellanki et al (2016) [38], in a trial of sitagliptin vs metformin and placebo in pre-selected African-American individuals with overweight or obesity in Atlanta USA with new or hyperglycaemia and unpro-voked ketosis or DKA and who had insulin discontinued within 12 weeks of initial presentation,…”
BackgroundAtypical Diabetes and Management Considerations
Patil, S. P. (2022) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2021.11.003 · Cited by 6
Stefanovski, D., Smiley, D. D., Punjabi, N. M., Umpierrez, G. E., & Vellanki, P. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae308 · Cited by 7
Self-citationUmpierrez, G. E., Vellanki, P., & Oladejo, O. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.03.007 · Cited by 2
Self-citationUncommon Presentations of Diabetes: Zebras in the Herd
Shidler, K. L., Letourneau, L. R., & Novak, L. M. (2019) · Clinical Diabetes · doi:10.2337/cd19-0019 · Cited by 4
“However, unlike patientswith type1diabetes, most will not require exogenous insulin for glucose management within a few weeks of the index DKA event (33,39).”
BackgroundJagannathan, R., Stefanovski, D., Smiley, D. D., Oladejo, O., Cotten, L. F., Umpierrez, G. E., & Vellanki, P. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.871965 · Cited by 3
“However, even a more rigorous HbA1c cutoff for initial remission showed that most people had dysglycemia on OGTT based on fasting and 2-h PG levels (3, 4).”
BackgroundMethodResultInfluentialSelf-citationRidout, S. A., Vellanki, P., & Nemenman, I. M. (2024) · eLife · doi:10.7554/elife.100193 · Cited by 5
“…et al., 2007 ) 8 Patient- to-patient variation in ability to achieve and sustain remission ( Mauvais-Jarvis et al., 2004b ; McFarlane et al., 2001 ; Vellanki et al., 2016 ; Umpierrez et al., 1997 ; Vellanki et al., 2020 ) Duration of remission is improved by (non-insulin) blood glucose management…”
InfluentialSelf-citationType 2 diabetes remission: multidimensional pharmacological strategies and future perspectives
Liu, Y., Gang, X., Liu, X., Jiang, W., Yang, Y., & Wang, G. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1687601 · Cited by 3
Ridout, S. A., Vellanki, P., & Nemenman, I. M. (2025) · eLife · doi:10.1101/2024.06.04.597343
“…after a few weeks or months of treatment with insulin, they are no longer dependent on insulin and can control blood sugar with diet or oral antidiabetic agents ( Mauvais-68 Jarvis et al., 2004b ; McFarlane et al., 2001 ; Vellanki et al., 2016 ; Umpierrez et al., 1997 ; Vellanki et al., 2020 ).”
Self-citationRidout, S. A., Vellanki, P., & Nemenman, I. M. (2024) · eLife · doi:10.7554/elife.100193.1
Self-citationRidout, S. A., Vellanki, P., & Nemenman, I. M. (2025) · eLife · doi:10.7554/elife.100193.2 · Cited by 1
Self-citation
Metadata
- Authors
- Vellanki, P., Smiley, D. D., Stefanovski, D., Anzola, I., Duan, W., Hudson, M., Peng, L., Pasquel, F. J., & Umpierrez, G. E.
- Affiliations
- Emory University (US)
- University of Pennsylvania (US)
- Corresponding author
- Vellanki, Priyathama
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-08-29
- Volume
- 39
- Issue
- 11
- Pages
- 1948-1955
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC5079604
- OpenAlex
- W2516960073
- Cited by
- 28
- References
- 34
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 4 · 2022: 6 · 2020: 3 · 2019: 5 · 2018: 3 · 2017: 1
- FWCI
- 3.02
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (K08-DK-0830361)
- National Institutes of Health Clinical Center (M01-RR-00039)
- Jacobs Family Foundation
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- metformin, sitagliptin, diabetic ketoacidosis, hyperglycemic crisis, African American patients, insulin sensitivity, beta-cell function, disposition index, oral glucose tolerance test, new-onset diabetes, obesity
- MeSH terms
- Sitagliptin Phosphate, Adolescent, Adult, Black or African American, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Glucose Tolerance Test, Humans, Hyperglycemia, Hypoglycemic Agents, Insulin Resistance, Longitudinal Studies, Male, Metformin, Middle Aged, Obesity, Prospective Studies, Body Mass Index, Single-Blind Method, Diabetic Ketoacidosis, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.